ENTRY       D03058                      Drug
NAME        Basiliximab (USAN/INN);
            Basiliximab (genetical recombination) (JAN);
            Simulect (TN)
PRODUCT     SIMULECT (Novartis Pharmaceuticals Corporation)
CLASS       Immunological agent
             DG02019  Interleukin inhibitor
REMARK      Therapeutic category: 6399
            ATC code: L04AC02
            Product: D03058<JP/US>
EFFICACY    Immunosuppressant, Anti-CD25 antibody
  DISEASE   Prophylaxis of acute organ rejection [DS:H00083]
  TYPE      Monoclonal antibody
TARGET      IL2RA (CD25) [HSA:3559] [KO:K05068]
  PATHWAY   hsa04060(3559)  Cytokine-cytokine receptor interaction
            hsa04144(3559)  Endocytosis
            hsa04630(3559)  JAK-STAT signaling pathway
            hsa04640(3559)  Hematopoietic cell lineage
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L04 IMMUNOSUPPRESSANTS
               L04A IMMUNOSUPPRESSANTS
                L04AC Interleukin inhibitors
                 L04AC02 Basiliximab
                  D03058  Basiliximab (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Immunological Agents
              Immunosuppressants
               Interleukin-2 Inhibitors
                Basiliximab
                 D03058  Basiliximab (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             6  Agents against pathologic organisms and parasites
              63  Biological preparations
               639  Miscellaneous
                6399  Others
                 D03058  Basiliximab (USAN/INN); Basiliximab (genetical recombination) (JAN)
            Drug groups [BR:br08330]
             Immunological agent
              DG02019  Interleukin inhibitor
               D03058  Basiliximab
            Drug classes [BR:br08332]
             Immunological agent
              DG02019  Interleukin inhibitor
               D03058  Basiliximab
            Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokine receptors
               Interleukin receptors
                IL2RA (CD25)
                 D03058  Basiliximab (USAN/INN) &lt;JP/US&gt;
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D03058
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D03058
DBLINKS     CAS: 179045-86-4
            PubChem: 17397213
            NIKKAJI: J1.892.794B
///
